Please assess the completion status of the following clinical trial:

Trial Title: One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion/ Exclusion Criteria~Key Inclusion Criteria:~* Adult participant (18 years and over)~  * treated for one of the following conditions: RA, AS, PsA, CD, UC.~ * either active substance naïve or treated with the originator or another biosimilar at baseline.~ * for whom the treating physician has decided to treat by (naïve) or switch from originator or another biosimilar to Flixabi or Imraldi.~ * participants who had initiated Flixabi or Imraldi at most 12 months before the baseline will also be included in the cohort.~* Paediatric participants (6-17 years):~  * treated for one of the following conditions: CD, UC.~ * either active substance naïve or treated with another biosimilar at baseline.~ * for whom the treating physician has decided to treat by (naïve) or switch to Flixabi (for both indications) or Imraldi (only for Crohn's disease).~ * participants who had initiated Flixabi or Imraldi at most 12 months before the baseline will also be included in the cohort.~Key Exclusion Criteria:~* Participant treated for psoriasis.~* Participant who are not to be followed up in the same investigator site for 2 years after baseline.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Flixabi (Type: None): Infliximab naive participants or participants who were previously treated with other infliximab biologics will receive Flixabi (infliximab) as prescribed by physician according to the local prescribing procedures.
- Imraldi (Type: None): Adalimumab naive participants or participants who were previously treated with other adalimumab biosimilars will receive Imraldi (adalimumab) as prescribed by physician according to the local prescribing procedures.

Based on this trial design, predict the completion outcome and termination type (if applicable).